Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    Advanced Search
    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Canadian Federal Government
        • Canadian Municipal Government
        • Canadian Provincial Government
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Advanced Search
    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • IR
    • All Products
    • Become a Client
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • General Enquiries
    • Media
    • Worldwide Offices
    • Hamburger menu
    • Cision Canada
    • Send a Release
    • FR
      • Phone

      • 877-269-7890 from 8 AM - 10 PM ET

      • ALL CONTACT INFO
      • Contact Cision

        877-269-7890
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • 3 News in Focus
      • 5 Business
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • IR
      • All Products
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media
      • Worldwide Offices
      • General Enquiries
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business) Business
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Research on Alzheimer's disease and related disorders - The FRQS and Pfizer Canada pledge $3.7M to fund a consortium and six research projects


      News provided by

      Fonds de recherche du Québec - Santé

      May 08, 2014, 15:35 ET

      Share this article

      Share this article


      MONTRÉAL, May 8, 2014 /CNW Telbec/ - The Fonds de recherche du Québec – Santé (FRQS) and Pfizer Canada are very pleased to announce $3.7M in funding by Pfizer Canada to support a consortium on the early detection of Alzheimer's disease and six related projects. The funding is provided through the Pfizer-FRQS Innovation Fund for Alzheimer's disease and related disorders, a research grant program overseen by the FRQS.

      "Thanks to this partnership with Pfizer Canada, our researchers now have the means to pool their expertise and undertake innovative projects. The scientists will have the opportunity to focus on determining markers and early treatment options for the disease. These measures will enable Québec's research community to become even more competitive in the field of Alzheimer's disease in Canada and abroad," affirmed Prof. Rémi Quirion, Québec's chief scientist and chairman of the board of directors of the FRQS.

      "Through the years, investigators in Québec have developed strong expertise in research on aging and on Alzheimer's disease in particular. This support will further accelerate breakthroughs for the greater benefit of Québecers," added Dr. Renaldo Battista, scientific director of the Fonds de recherche du Québec – Santé.

      "The consortium and the innovative projects will tackle health issues that are of major importance to Québecers and mobilize multidisciplinary teams of expert researchers in the province's leading institutions. Pfizer Canada is proud to support these initiatives since they reaffirm our drive to pursue its involvement in research development in Québec," stated Dr. Vratislav Hadrava, Vice President and Medical Director, Pfizer Canada.

      The grant program was so successful that the FRQS and Pfizer plan to launch a second edition of the innovative projects competition in July 2014.

      Creation of a consortium for the early detection of Alzheimer's disease
      The Consortium pour l'identification précoce de la maladie d'Alzheimer – Québec (CIMA-Q) aims to develop means to provide an earlier diagnosis of Alzheimer's and better understand the causes of the disease so as to develop effective treatment options. The consortium is led by Sylvie Belleville, researcher and director of research centre of the Institut universitaire de gériatrie de Montréal, affiliated with the Université de Montréal, and by Andréa LeBlanc, researcher at the Bloomfield Centre for Research in Aging of the Lady Davis Institute for Medical Research. The CIMA-Q brings together over 90 Québec researchers in fields related to Alzheimer's disease. The group will receive $2.5M in funding over three years.

      Support for six high-risk projects with significant potential benefits
      Researchers affiliated with several Québec universities will pilot the six projects supported by the Pfizer-FRQS Innovation Fund for Alzheimer's disease and related disorders. Each initiative will receive up to $200,000 to better understand the disease, validate the most effective diagnostic methods and determine new therapeutic approaches.

      The six Alzheimer's Fund projects are (alphabetically by PI surname):

      1. Marc-André Bédard, Montréal Neurological Institute / UQAM
      Validating 18F-Fluoroethoxybenzovesamicol (FEOBV) as a biomarker of Alzheimer disease

      2. Frédéric Calon, Centre de recherche du CHUQ / Université Laval
      Gene therapy to increase glucose uptake: application in an animal model of Alzheimer disease

      3. Claudio Cuello, McGill University
      New, non-invasive tools for the early detection of the pathology of Alzheimer disease

      4. Jean-Pierre Julien, Université Laval
      Nanobodies targeting TDP-43 for the treatment of neurodegenerative diseases

      5. Nicole Leclerc, Université de Montréal
      Mechanisms involved in the propagation of tau pathology in Alzheimer disease

      6. Keith Murai, McGill University Health Centre / McGill University
      Investigations into microglia-astrocyte interactions in Alzheimer disease

      The creation of the consortium and the launch of the six projects will lead to unprecedented Alzheimer research and researcher and institutional collaborations. More specifically, the funding will help create an environment that will provide Québec scientists with the methodological tools, platforms and knowledge required to foster research innovation, cohesion and visibility in the field of Alzheimer's disease.

      Québec, Canada and several countries around the world have targeted Alzheimer's disease prevention, treatment and research as a health priority. In this regard, since May 2009, Québec has relied on a report entitled Relever le défi de la maladie d'Alzheimer et des maladies apparentées – une vision centrée sur la personne, l'humanisme et l'excellence, which sets out 24 recommendations on different aspects of the disease, from awareness building to research.

      About the Fonds de recherche du Québec – Santé (FRQS)
      The mission of the Fonds de recherche du Québec – Santé (FRQS), which reports to the Minister of Higher Education, Research and Science, is to support health research to foster the wellness of Québec's population. Its mandate is to promote and financially support such research, to disseminate knowledge and train researchers, to forge the partnerships necessary for the development of Quebec's research and innovation system, and, lastly, to advance research internationally. For further information, visit www.frqs.gouv.qc.ca.

      About Pfizer Canada
      Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. Our diversified health care portfolio includes some of the world's best-known and most prescribed medicines and vaccines. Every day, Pfizer Canada employees work to bring therapies to patients that significantly improve their lives. The company is a major contributor to health research in Canada. We apply science and our global resources to improve the health and well-being of Canadians at every stage of life. Our commitment is reflected in everything Pfizer does, from our disease awareness initiatives to our community partnerships, to our belief that it takes more than medication to be truly healthy. To learn more about Pfizer's More than Medication philosophy and programs, visit www.morethanmedication.ca. To learn more about Pfizer Canada, visit pfizer.ca.

       

      SOURCE: Fonds de recherche du Québec - Santé

      Vincent Lamoureux, Pfizer Canada, 514-426-6841, [email protected] ;Michelle Dubuc, Communications and knowledge mobilization, Fonds de recherche du Québec, 514-873-2114, ext. 1235, [email protected]

      Modal title

      Organization Profile

      Fonds de recherche du Québec - Santé

      Contact PR Newswire

      • 866-245-2317
        from 7:30 AM - 6:30 PM ET
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • Investor Relations

      About

      • About PR Newswire
      • About Cision
      • Careers
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • Platform Login
      • Privacy Policy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Platform
      • Next Gen Communications Cloud
      • Cision Communications Cloud
      • my CNW
      877-269-7890
      from 8 AM - 10 PM ET
      • Terms of Use
      • Information Security Policy
      • Site Map
      • Cookie Settings
      • Accessibility Statement
      Copyright © 2026 CNW Group Ltd. All Rights Reserved. A Cision company.